Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Update

by · The Markets Daily

Citius Oncology, Inc. (NASDAQ:CTOR – Get Free Report) saw a significant growth in short interest during the month of December. As of December 15th, there was short interest totaling 650,544 shares, a growth of 193.4% from the November 30th total of 221,699 shares. Approximately 0.8% of the shares of the stock are sold short. Based on an average daily volume of 933,057 shares, the short-interest ratio is presently 0.7 days. Based on an average daily volume of 933,057 shares, the short-interest ratio is presently 0.7 days. Approximately 0.8% of the shares of the stock are sold short.

Citius Oncology Price Performance

CTOR stock traded down $0.02 during trading on Friday, hitting $1.13. The company had a trading volume of 307,556 shares, compared to its average volume of 968,080. The business has a 50 day moving average of $1.36 and a 200 day moving average of $1.89. The company has a current ratio of 0.56, a quick ratio of 0.02 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $95.82 million, a price-to-earnings ratio of -3.32 and a beta of 2.98. Citius Oncology has a fifty-two week low of $0.55 and a fifty-two week high of $6.19.

Citius Oncology (NASDAQ:CTOR – Get Free Report) last issued its quarterly earnings results on Tuesday, December 23rd. The company reported ($0.06) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.06).

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. IFP Advisors Inc grew its stake in shares of Citius Oncology by 49.5% in the third quarter. IFP Advisors Inc now owns 33,215 shares of the company’s stock worth $67,000 after acquiring an additional 11,000 shares during the last quarter. Armistice Capital LLC bought a new stake in shares of Citius Oncology during the 3rd quarter valued at $15,582,000. Citadel Advisors LLC bought a new position in shares of Citius Oncology during the third quarter worth $36,000. Bank of America Corp DE grew its position in shares of Citius Oncology by 5,256.9% in the 2nd quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock valued at $37,000 after purchasing an additional 8,411 shares during the period. Finally, Jane Street Group LLC bought a new position in Citius Oncology during the 2nd quarter worth about $465,000. 70.52% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on CTOR. Maxim Group raised shares of Citius Oncology from a “hold” rating to a “buy” rating and set a $6.00 target price for the company in a research note on Tuesday, September 23rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Citius Oncology in a report on Monday. Finally, Citigroup raised Citius Oncology from a “hold” rating to a “buy” rating in a research report on Tuesday, September 23rd. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Citius Oncology has an average rating of “Hold” and an average target price of $6.00.

View Our Latest Stock Report on Citius Oncology

Citius Oncology Company Profile

(Get Free Report)

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Recommended Stories